Abstract
Indoor residual spraying (IRS) is one of the main vector control tools used in malaria prevention. This study evaluates IRS in the context of a privately run campaign conducted across a low-lying, irrigated, sugarcane estate from Illovo Sugar, in the Chikwawa district of Malawi. The effect of Actellic 300CS annual spraying over four years (2015-2018) was assessed using a negative binomial mixed effects model, in an area where pyrethroid resistance has previously been identified. With an unadjusted incidence rate ratio (IRR) of 0.38 (95% CI: 0.32 – 0.45) and an adjusted IRR of 0.50 (95% CI: 0.42-0.59), IRS has significantly contributed to a reduction in case incidence rates at Illovo, as compared to control clinics and time points outside of the six month protective period. This study shows how the consistency of a privately run IRS campaign can improve the health of employees. More research is needed on the duration and timing of IRS programmes.
Competing Interest Statement
Dr. Albert Kumbwa is employed by Illovo Sugar as the main clinician at Illovo Sugar Nchalo. Peter Nasoni was employed as the public health officer at the time of data collection.
Funding Statement
This work was funded by the Medical Research Council through the Medical Research Council Doctoral Training Partnership (1965090) awarded to Remy Hoek Spaans through the Liverpool School of Tropical Medicine and Lancaster University.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Not Applicable
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical Approval for this study has been granted by College of Medicine Research and Ethics Committee (COMREC) and the Liverpool School of Tropical Medicine (LSTM)
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Not Applicable
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Not Applicable
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Not Applicable
Footnotes
↵* remyhoekspaans{at}gmail.com
Data Availability
All datasets and metadate required to reproduce the analysis are published open access on Zenodo. Access via: 10.5281/zenodo.8146044
